Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Intra-Arterial Infusion with Methotrexate in the Rat

Abstract

The superiority of intra-arterial infusion with methotrexate (MTX) over its systemic use in the treatment of head and neck tumours is still being questioned. A model in the rat, suitable for intra-arterial administration of MTX could be constructed. In this model 3 schedules have been investigated: (1) 7 days continuous intra-arterial infusion with MTX; (2) the same schedule combined with leucovorin (CF) 6-hourly intraperitoneally (i.p.) after Sullivan et al. (1959); (3) intermittent administration of MTX 2 × 24 h intra-arterial infusion on Day 1 and 4, while on Day 2, 3, 5, 6 and 7 the catheter is kept open by the continuous intra-arterial infusion of saline. For all the three schedules intra-arterial MTX proved to be superior to its systemic use.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sindram, P., Snow, G. & van Putten, L. Intra-Arterial Infusion with Methotrexate in the Rat. Br J Cancer 30, 349–354 (1974). https://doi.org/10.1038/bjc.1974.204

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1974.204

This article is cited by

Search

Quick links